Overview

The global Cobalt-60 Sterilization Market was valued at approximately USD 1.59 billion in 2025 and is projected to reach USD 2.65 billion by 2034, expanding at a CAGR of approximately 5.8% during 2026-2034. The market is driven by rising global production of single-use medical devices, tightening regulatory restrictions on ethylene oxide sterilization, and continued investment in securing long-term Cobalt-60 supply chains through nuclear reactor harvesting partnerships in North America. The market is shifting from conventional reliance on a small number of legacy Cobalt-60 harvesting reactors in Canada toward a more geographically diversified supply base, as North American utilities pursue new domestic harvesting capability and contract sterilization providers expand X-ray and electron-beam capacity alongside their existing gamma networks to reduce single-modality dependence. Government initiatives such as the U.S. Environmental Protection Agency's final National Emission Standards for Hazardous Air Pollutants for commercial ethylene oxide sterilization facilities, which impose stricter emission control requirements on EtO sterilizers, are encouraging medical device and pharmaceutical manufacturers to shift a greater share of sterilization volume toward gamma and other radiation-based methods that do not carry the same emissions compliance burden. BY region, North America held the largest share of the Cobalt-60 sterilization market in 2025, supported by its concentration of contract sterilization providers and its role as the primary global source of harvested Cobalt-60. Asia Pacific is expected to grow at the fastest CAGR during the forecast period, driven by expanding medical device and pharmaceutical manufacturing capacity and rising outsourcing of sterilization to specialized contract providers across China, India, and Japan.

Market Size & Share

Market Dynamics

KEY MARKET TREND

Diversification of Sterilization Modality Portfolios to Strengthen Supply Chain Resilience is an Emerging Trend

• Contract sterilization providers are increasingly building X-ray and electron-beam capacity alongside their existing gamma sterilization networks, allowing customers to qualify multiple irradiation technologies for the same product and reducing reliance on any single sterilization modality or Cobalt-60 supply source during periods of tight availability.
• Reactor operators and isotope companies are developing new source-production technologies, including specially configured adjuster rods that increase Cobalt-60 yield without altering reactor power output, enabling higher harvest volumes from existing nuclear units rather than requiring new reactor construction to expand global supply.
• Medical device and pharmaceutical manufacturers are increasingly qualifying their products across two or more sterilization modalities as part of supply chain risk management, a practice reinforced by regulatory guidance encouraging validated backup sterilization methods to avoid single-source dependency on any one irradiation technology.
• Westinghouse Electric Company, Nordion (a Sotera Health company), and PSEG Nuclear announced key milestones toward establishing the first-ever commercial-scale production of Cobalt-60 in U.S. Pressurized Water Reactors, aimed at building a domestic U.S. supply chain for an isotope currently used to sterilize more than 16 billion single-use medical devices each year in the country.

 

KEY MARKET DRIVER

Regulatory Pressure to Reduce Ethylene Oxide Use is the Key Driver

• Ethylene oxide remains the most widely used sterilization method for temperature-sensitive medical devices, but its classification as a carcinogenic air pollutant has led regulators to impose stricter emission controls, prompting manufacturers to evaluate Cobalt-60 gamma sterilization as a proven, already-validated alternative for a growing share of device types.
• Gamma sterilization's ability to penetrate dense packaging and multi-layered device assemblies without requiring aeration time makes it well suited to high-volume, pre-packaged single-use devices, supporting continued reliance on Cobalt-60 even as some lower-density product categories shift toward electron-beam or X-ray alternatives.
• Standards bodies including ISO, through ISO 11137 for radiation sterilization of health care products, and AAMI continue to update sterility assurance and dose-setting guidance, giving manufacturers a well-established regulatory pathway for qualifying Cobalt-60 gamma sterilization that is not yet as mature for some newer sterilization technologies.
• The U.S. Environmental Protection Agency finalized National Emission Standards for Hazardous Air Pollutants for commercial ethylene oxide sterilization facilities, requiring significant reductions in EtO emissions from covered facilities and creating compliance pressure that is expected to support continued or increased reliance on gamma sterilization for applicable product lines.

 

KEY MARKET OPPORTUNITY

Expansion of Domestic Cobalt-60 Production Capacity Creating Significant Market Opportunity

• Utilities operating pressurized water reactors in the United States are exploring Cobalt-60 harvesting as a new, incremental revenue stream from existing nuclear assets, creating an opportunity to establish domestic source production capacity in a market that has historically depended almost entirely on Canadian CANDU reactor harvesting.
• Contract sterilization providers operating dedicated on-site facilities for large medical device and pharmaceutical customers represent an emerging business model that offers customers greater supply security and shorter logistics chains compared with shipping products to centralized, shared contract sterilization sites.
• Ontario's provincial government has set a policy goal of doubling medical isotope production by 2030, creating an investment-supportive environment for continued Cobalt-60 harvesting capacity growth at existing Canadian reactor sites, which remain the world's largest source of the isotope.
• Bruce Power completed the largest Cobalt-60 harvest in its more than 40-year production history during its Unit 5 planned outage in 2025, an achievement that included upgrades enabling increased future production of both standard and high-specific-activity Cobalt-60, directly expanding the available global supply base for sterilization and medical use.

Cobalt-60 Sterilization Market Size, 2025-2034 (USD Billion)

Segmentation Analysis

Analysis by Service Type

Contract sterilization services held the largest share of the Cobalt-60 sterilization market in 2025 because the great majority of medical device and pharmaceutical manufacturers outsource terminal sterilization to specialized providers rather than operating their own gamma irradiation facilities, given the regulatory, licensing, and capital burden of owning a Cobalt-60 source. Providers operating dedicated gamma networks across North America, Europe, and Asia process high volumes of pre-packaged devices under long-term customer contracts, generating recurring, volume-linked revenue that scales directly with global medical device output. This outsourced service model remains structurally dominant because few manufacturers have the regulatory expertise or scale to justify owning and maintaining a licensed Cobalt-60 irradiator themselves.

 

Sterilization validation services are projected to grow at the fastest CAGR during the forecast period, driven by tightening regulatory expectations under ISO 11137 and AAMI guidance for dose-setting, sterility assurance level verification, and process re-qualification. As manufacturers increasingly qualify products across multiple sterilization modalities to build supply chain resilience, each additional qualified pathway requires its own dedicated validation study, expanding demand for specialized validation work at a pace faster than the underlying volume of physical sterilization itself. A documented shortage of qualified sterilization validation specialists, particularly in Southeast Asia and Africa, is further widening the gap between validation service demand and available capacity, reinforcing this segment's above-market growth trajectory.

 

Service Type categories include

                       ·           Contract Sterilization Services (Dominating Segment)

                       ·           Sterilization Validation Services (Fastest-growing Segment)

                       ·           Dosimetry Services

                       ·           Cobalt-60 Source Supply

                       ·           Irradiation Equipment Manufacturing

                       ·           Others

 

Analysis by Application

Medical devices accounted for the largest share of Cobalt-60 sterilization demand in 2025, reflecting gamma sterilization's established role as the preferred terminal sterilization method for pre-packaged, disposable devices such as catheters, syringes, surgical kits, and wound-care products that require high-penetration processing without added heat. Cobalt-60 is used to sterilize more than 16 billion single-use medical devices annually in the United States alone, illustrating the sheer scale of this application relative to other end uses. The combination of high global device volumes and long-established regulatory validation pathways keeps medical devices the structurally dominant application for Cobalt-60 sterilization.

 

Pharmaceutical products are projected to grow at the fastest CAGR during the forecast period, supported by rising output of prefilled syringes, combination products, and single-use bioprocessing components that require terminal or component-level sterilization before aseptic filling. Growth in biologics and cell and gene therapy manufacturing is increasing demand for gamma-sterilized single-use assemblies and connectors used in closed-system bioprocessing, a segment that is expanding faster than traditional medical device sterilization volumes as biopharmaceutical manufacturing capacity continues to scale globally.

 

Application categories include

               ·           Medical Devices (Dominating Segment)

               ·           Pharmaceutical Products (Fastest-growing Segment)

               ·           Food Products

               ·           Agricultural Products

               ·           Cosmetic Products

               ·           Personal Care Products

               ·           Others

 

Analysis by Sterilization Facility Model

Off-site centralized contract facilities held the largest share in 2025 because most medical device and pharmaceutical manufacturers ship products to shared, multi-customer gamma sterilization sites rather than building dedicated capacity of their own, allowing contract providers to achieve higher facility utilization and offer competitive per-unit processing costs. This centralized model has been the industry standard for decades, supported by well-established logistics networks connecting manufacturing sites to a limited number of licensed Cobalt-60 irradiation facilities across major manufacturing regions.

 

Dedicated on-site contract facilities are projected to grow at the fastest CAGR during the forecast period, as large medical device and pharmaceutical manufacturers increasingly contract sterilization providers to build and operate facilities located at or near their own manufacturing sites, reducing transportation time, improving supply chain security, and lowering the risk of disruption from centralized facility outages. This model has gained traction following past instances of regional sterilization capacity constraints that exposed the risks of concentrated, shared facility networks.

 

Sterilization Facility Model categories include

               ·           Off-Site Centralized Contract Facilities (Dominating Segment)

               ·           Dedicated On-Site Contract Facilities (Fastest-growing Segment)

               ·           Captive In-House Facilities

 

Analysis by Irradiator Type

Panoramic wet-storage irradiators held the largest share in 2025 because this design, in which Cobalt-60 sources are stored underwater in a shielded pool and raised into position only during processing, remains the standard configuration for the majority of commercial-scale contract sterilization facilities worldwide. These irradiators offer a proven balance of operator safety, source shielding reliability, and high processing throughput for large pallet and tote volumes, and the large installed base of this irradiator type across existing global contract sterilization networks continues to anchor its dominant position.

 

Continuous-flow, high-throughput irradiators are projected to grow at the fastest CAGR during the forecast period, as new capacity additions increasingly favor designs that move product through the irradiation chamber in a continuous cycle rather than in discrete batches, improving dose uniformity and processing speed for high-volume customers. Rising global device production volumes are prompting contract sterilization providers to prioritize this irradiator configuration when adding new gamma capacity, supporting faster growth for this design relative to older batch-oriented irradiator installations.

 

Irradiator Type categories include

               ·           Panoramic Wet-Storage Irradiators (Dominating Segment)

               ·           Continuous-Flow High-Throughput Irradiators (Fastest-growing Segment)

               ·           Compact Self-Shielded Irradiators

               ·           Others

 

Analysis by Region

North America held the largest share of the Cobalt-60 sterilization market in 2025, supported by its concentration of contract sterilization providers, its position as home to the world's primary Cobalt-60 harvesting reactors in Ontario, Canada, and the scale of its medical device manufacturing base, which relies on gamma sterilization for more than 16 billion single-use devices annually in the United States alone. The region's well-established regulatory pathways under FDA and Health Canada frameworks further reinforce its position as the largest and most mature Cobalt-60 sterilization market globally.

 

Asia Pacific is projected to grow at the fastest CAGR during the forecast period, driven by expanding medical device and pharmaceutical manufacturing capacity in China, India, and Japan, and by rising outsourcing of sterilization to specialized contract providers as regional healthcare infrastructure investment increases. China's growing domestic Cobalt-60 source production capability, alongside continued capacity investment by regional and international contract sterilization providers, is expected to support faster growth in this region relative to the more mature North American and European markets.

 

Region categories include

               ·           North America (Dominating Region)

               ·           Asia Pacific (Fastest-growing Region)

               ·           Europe

               ·           Latin America

               ·           Middle East and Africa

By Region

Cobalt-60 Sterilization Market Regional Analysis

Regional Analysis

North America held the largest share of the Cobalt-60 sterilization market in 2025, supported by its concentration of contract sterilization providers, its position as home to the world's primary Cobalt-60 harvesting reactors in Ontario, Canada, and the scale of its medical device manufacturing base, which relies on gamma sterilization for more than 16 billion single-use devices annually in the United States alone. The region's well-established regulatory pathways under FDA and Health Canada frameworks further reinforce its position as the largest and most mature Cobalt-60 sterilization market globally.

 

Asia Pacific is projected to grow at the fastest CAGR during the forecast period, driven by expanding medical device and pharmaceutical manufacturing capacity in China, India, and Japan, and by rising outsourcing of sterilization to specialized contract providers as regional healthcare infrastructure investment increases. China's growing domestic Cobalt-60 source production capability, alongside continued capacity investment by regional and international contract sterilization providers, is expected to support faster growth in this region relative to the more mature North American and European markets.

 

Countries and Regions Covered

North America (Dominating Region)

o    United States (Largest Country Market)

o    Canada (Largest Cobalt-60 Source Producer)

o    Mexico

Asia Pacific (Fastest-Growing Region)

o    China (Largest Country Market)

o    India (Fastest-Growing Country Market)

o    Japan

o    Rest of Asia-Pacific

Europe

o    Germany (Largest Country Market)

o    France

o    United Kingdom

o    Rest of Europe

Latin America

o    Brazil (Largest Country Market)

o    Rest of Latin America

Middle East and Africa

o    South Africa (Largest Country Market)

o    Rest of Middle East and Africa

Market Share

The global Cobalt-60 sterilization market is consolidated at the contract-services level, led by Sotera Health (Sterigenics and Nordion) and STERIS ,which together operate the largest global networks of gamma sterilization facilities, while a smaller number of regional providers, including BGS Beta-Gamma-Service and Ionisos, serve customers across Europe. Source supply is even more concentrated, with Canada's Bruce Power and Nordion historically providing the majority of the world's Cobalt-60, alongside smaller volumes from Russia's Isotope JSC, China's CIRC, and other national producers. Key success factors include reliable long-term source supply agreements, multi-modality technology offerings, and regulatory expertise supporting customer validation. Leading companies are prioritizing supply chain diversification, including new domestic Cobalt-60 production initiatives and expanded X-ray and electron-beam capacity, alongside continued network expansion to meet rising device manufacturing volumes.

 

Key Players

           ·           Sotera Health Company (United States)

           ·           STERIS plc (Ireland)

           ·           BGS Beta-Gamma-Service GmbH & Co. KG (Germany)

           ·           Ionisos SAS (France)

           ·           Best Theratronics Ltd (Canada)

           ·           Bruce Power (Canada)

           ·           National Centre for Nuclear Research - POLATOM (Poland)

           ·           Eckert & Ziegler AG (Germany)

           ·           NTP Radioisotopes SOC Ltd (South Africa)

           ·           Isotope JSC (Russia)

           ·           Institute of Isotopes Co. Ltd. - IZOTOP (Hungary)

           ·           China Isotope & Radiation Corporation (CIRC) (China)

           ·           Ontario Power Generation (OPG) (Canada)

           ·           Nuclear Power Corporation of India Limited (NPCIL) / BRIT (India)

           ·           Atomic Energy of Canada Limited (AECL) (Canada)

 

Recent Market Developments

• In May 2025, Sterigenics announced the expansion of its Haw River, North Carolina campus to add a new irradiation facility directly adjacent to its existing gamma sterilization site, increasing total regional irradiation capacity and giving customers greater modality flexibility to serve growing medical device and pharmaceutical demand in the southeastern United States.
• In November 2025, The Source Security Working Group, an industry coalition representing sterilization and healthcare supply chain interests, urged the U.S. Trade Representative to exclude Canadian-origin Cobalt-60 from proposed tariffs, warning that added duties on this critical medical isotope could disrupt sterilization supply for U.S. healthcare and medical device manufacturing.
• In January 2026, Westinghouse Electric Company, Nordion (a Sotera Health company), and PSEG Nuclear announced key milestones in their joint initiative to establish the first-ever commercial-scale production of Cobalt-60 in U.S. Pressurized Water Reactors, aimed at building a domestic U.S. supply chain to reduce reliance on Canadian-sourced material.
• In March 2026, Bruce Power completed a Cobalt-60 harvest during its Unit 8 planned outage using newly developed heavy adjuster rod technology, the first harvest to increase Co-60 yield without affecting reactor power output, with the material subsequently delivered to Nordion for processing and global distribution.
• In April 2026, Sterigenics marked the ribbon-cutting opening of its new irradiation facility at its Haw River, North Carolina campus, located directly adjacent to its existing gamma sterilization site, providing customers with additional processing capacity and supply chain resilience across multiple irradiation technologies at a single campus.

Frequently Asked Questions